A Phase I Study of 9MW4113 Injection Versus Dupixent®

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
It is a randomized, double‐blinded, parallel, single‐dose, Phase I comparative study toevaluate the pharmacokinetic, safety, and immunogenicity similarity between 9MW4113 andDupixent® in healthy Chinese adult participants. A total of 208 healthy participants areplanned to be included and randomized at a ratio of 1:1 to receive single 300mg/2.0ml9MW4113 injection or Dupixent®.
Epistemonikos ID: 503b2e2aa47d4acc098cf377280c1ba8dd6bf646
First added on: Aug 27, 2026